George Trainor

George brings Rappta more than thirty years of experience in the biotechnology and pharmaceutical Industries. He was Vice President of Oncology and Early Discovery Chemistry at Bristol Myers Squibb Company with responsibility for all aspects of medicinal chemistry for the oncology area as well as hit-to-leads activities in support of all therapeutic areas. George has led teams of over 100 scientists and has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. Prior to BMS George was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. This breakthrough technology was subsequently employed in the sequencing of the human genome, and In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing. Dr. Trainor did his undergraduate work at the Stevens Institute of Technology, received his Ph.D. in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.